Valneva SE/€VLA
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Valneva SE
Valneva SE is a biotechnology company specializing in the development and commercialization of vaccines for infectious diseases. The company's portfolio includes vaccines for diseases such as Japanese encephalitis and cholera. Valneva is actively engaged in developing vaccines for Lyme disease and chikungunya. Founded in 2013 through the merger of Intercell AG and Vivalis, Valneva is headquartered in Saint-Herblain, France. The company operates primarily in Europe but has a global reach through various strategic partnerships and licensing agreements. Valneva's competitive strength lies in its focus on addressing unmet medical needs with its diverse pipeline of innovative vaccine candidates.
Ticker
€VLA
Sector
Primary listing
PAR
Industry
Biotechnology
Headquarters
Employees
713
Website
Valneva SE Metrics
BasicAdvanced
€551M
-
-€0.54
1.10
-
Price and volume
Market cap
€551M
Beta
1.1
52-week high
€4.24
52-week low
€1.73
Average daily volume
368K
Financial strength
Current ratio
2.703
Quick ratio
1.756
Long term debt to equity
107.697
Total debt to equity
120.481
Interest coverage (TTM)
-6.60%
Profitability
EBITDA (TTM)
-135.785
Gross margin (TTM)
5.74%
Net profit margin (TTM)
-43.21%
Operating margin (TTM)
-81.28%
Effective tax rate (TTM)
-2.85%
Revenue per employee (TTM)
€260,000
Management effectiveness
Return on assets (TTM)
-19.19%
Return on equity (TTM)
-44.11%
Valuation
Price to revenue (TTM)
2.605
Price to book
2.84
Price to tangible book (TTM)
3.31
Price to free cash flow (TTM)
-8.034
Free cash flow yield (TTM)
-12.45%
Free cash flow per share (TTM)
-40.45%
Growth
Revenue change (TTM)
21.64%
Earnings per share change (TTM)
206.84%
3-year revenue growth (CAGR)
-18.74%
10-year revenue growth (CAGR)
12.99%
3-year earnings per share growth (CAGR)
-8.59%
10-year earnings per share growth (CAGR)
12.84%
Bulls say / Bears say
Valneva received the first marketing authorization for its chikungunya vaccine, IXCHIQ®, in Brazil, marking a significant milestone in expanding its market presence in endemic regions. (globenewswire.com)
The company reported positive Phase 2 booster results for its Lyme disease vaccine candidate, VLA15, developed in partnership with Pfizer, indicating strong immune responses across all age groups. (pfizer.com)
Valneva secured up to $41.3 million in additional funding from CEPI to enhance global access to its chikungunya vaccine, supporting post-marketing trials and potential label extensions. (delveinsight.com)
Analysts have slashed Valneva's revenue estimates for 2025 by 13%, indicating a more pessimistic outlook on the company's financial performance. (simplywall.st)
The company has postponed debt payments, deferring reimbursements of its first $100 million loan tranche to January 2026, which may signal cash flow concerns. (tipranks.com)
Short interest in Valneva's stock increased by 191.4% as of March 15, 2025, suggesting growing bearish sentiment among investors. (marketbeat.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Valneva SE stock?
Valneva SE (VLA) has a market cap of €551M as of July 28, 2025.
What is the P/E ratio for Valneva SE stock?
The price to earnings (P/E) ratio for Valneva SE (VLA) stock is 0 as of July 28, 2025.
Does Valneva SE stock pay dividends?
No, Valneva SE (VLA) stock does not pay dividends to its shareholders as of July 28, 2025.
When is the next Valneva SE dividend payment date?
Valneva SE (VLA) stock does not pay dividends to its shareholders.
What is the beta indicator for Valneva SE?
Valneva SE (VLA) has a beta rating of 1.1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.